Vaccine
No approved hantavirus vaccine exists in the US or Europe.
Despite decades of research, hantavirus vaccine development has been slow. The virus's low incidence makes large clinical trials difficult to fund and conduct. Prevention through rodent control remains the primary defense.
Why is there no vaccine?
- Low case numbers: HPS affects 20 to 40 people per year in the US. Pharmaceutical companies have little financial incentive to develop a vaccine for a rare disease.
- Multiple strains: Different hantavirus species cause disease across different continents. A single vaccine would need to protect against Sin Nombre (Americas), Andes (South America), Hantaan (Asia), and others.
- No good animal model: Historically, hantaviruses don't cause disease in most lab animals the same way they do in humans, making it difficult to test vaccine candidates before human trials.
- Funding gaps: Hantavirus research receives a fraction of the funding given to more common infectious diseases.
Vaccine candidates and trials
Hantavax (Inactivated virus)
Approved (limited use)South Korea / ChinaAn inactivated whole-virus vaccine used in South Korea and China since the 1990s. Provides partial protection against HFRS-causing strains (Hantaan and Seoul viruses). Requires multiple doses. Effectiveness data is limited by study design, with estimates ranging from 30% to 70%. Not approved in the US or Europe.
DNA vaccine candidates
Phase 1 / Phase 2 trialsUnited StatesSeveral DNA-based vaccines targeting the Gn and Gc glycoproteins of Sin Nombre and Andes viruses have entered early clinical trials. These vaccines use plasmid DNA to teach cells to produce hantavirus proteins, triggering an immune response. Results from Phase 1 trials show the vaccines are safe and produce neutralizing antibodies, but large-scale efficacy trials have not yet been completed.
mRNA vaccine platforms
PreclinicalGlobalFollowing the success of mRNA technology against COVID-19, researchers are exploring mRNA-based hantavirus vaccines. These are in early preclinical stages. The approach could enable faster development and manufacturing, but no human trials have begun.
Virus-like particle (VLP) vaccines
PreclinicalUnited States / EuropeVLP vaccines mimic the structure of hantavirus without containing genetic material, making them non-infectious. Animal studies show strong immune responses. VLPs are considered a promising approach but remain years from human trials.
When will a vaccine be available?
There is no firm timeline. The most advanced Western candidates (DNA vaccines) are in early clinical trials, which typically require 5 to 10 more years before potential approval. The mRNA approach could accelerate this timeline, but hantavirus vaccine development lacks the urgency and funding that drove rapid COVID-19 vaccine creation.
Until a vaccine becomes available, prevention through rodent control remains the only reliable protection against hantavirus.